{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008249028,0.0004252307,0.001658713,0.0004234684,0.00005049731,0.000005214655,0.0003099437,0.0002044239,0.0005287065],"category_scores_gemma":[0.0001187148,0.0003113406,0.000104322,0.001059228,0.001117121,0.0003305318,0.00006786959,0.0005880766,0.000002245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002576988,"about_ca_system_score_gemma":0.0009079584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001680168,"about_ca_topic_score_gemma":0.0001519643,"domain_scores_codex":[0.9958051,0.0004989966,0.001236815,0.0006071044,0.001187426,0.0006645039],"domain_scores_gemma":[0.9970915,0.001466271,0.0005772582,0.0003942134,0.0002426967,0.0002280944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.568946,0.002565065,0.002403034,0.00003627621,0.0002088671,0.00007326146,0.0005420698,0.00008733958,0.0004594721,0.0000765626,0.000006189832,0.4245959],"study_design_scores_gemma":[0.9492896,0.02887766,0.008946215,0.0002706157,0.00006929176,0.00003717082,0.0002623628,0.0002437464,0.0009863175,0.0006868613,0.01001485,0.000315296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980725,0.01008897,0.001059784,0.002196681,0.0008011831,0.004871085,0.000113436,0.0000717459,0.00007210241],"genre_scores_gemma":[0.9679568,0.02882211,0.0007962419,0.0007241347,0.0004101239,0.0010714,0.00008391463,0.00007604025,0.0000591705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4242806,"threshold_uncertainty_score":0.9999338,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0373529934834873,"score_gpt":0.3836976276393478,"score_spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}